Serum Testosterone Levels Are Negatively Correlated with International Prostate Symptom Score and Transitional Prostate Volume

Shim, Ji Sung; Kim, Jaehwan; Yoon, Yong Sik; Choi, Hoon; Park, Jae Young; Bae, Jae Hyun

doi:10.1111/luts.12150

Cited by 13 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 In the present study, although the authors stated that the patients in both groups have a normal pituitary-gonadal axis, the testosterone levels of the patients were not mentioned. The authors demonstrated the important role of the nervous system in the development of benign prostate hyperplasia (BPH).…”

contrasting

confidence: 52%

“…Shim et al reported that total testosterone levels showed a significant negative correlation with transitional prostate volume in their study. 1 In the present study, although the authors stated that the patients in both groups have a normal pituitary-gonadal axis, the testosterone levels of the patients were not mentioned. If the testosterone levels were presented, the study would be more significant.…”

contrasting

confidence: 52%

See 1 more Smart Citation

How do testosterone and prostate‐specific antigen levels affect the prostate volume in patients with spinal cord injury?

Gül

2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

contrasting

confidence: 52%

contrasting

confidence: 52%

How do testosterone and prostate‐specific antigen levels affect the prostate volume in patients with spinal cord injury?

Gül

2019

Neurourology and Urodynamics

View full text Add to dashboard Cite

“…The most common cause of LUTS in men is prostate enlargement and progression of BPH. A number of studies have suggested that an inverse association exist between serum T levels and LUTS; however, the underlying biochemical and physiological mechanisms by which reduced T levels affect LUTS have yet to be fully delineated [70717273]. A significantly larger prostate volume was reported in men afflicted with Met S [1921747576], however it is unclear if this increase in prostate volume indeed exerts a clinical significance [32].…”

Section: Metabolic Syndrome Testosterone Deficiency and Pathophysiomentioning

confidence: 99%

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Traish

Johansen

2018

World J Mens Health

View full text Add to dashboard Cite

Lower urinary tract function is modulated by neural, vascular and urethral and bladder structural elements. The pathophysiological mechanisms of lower urinary tract symptoms (LUTS) encompass prostate enlargement, alterations in urethra histological structure bladder fibrosis and alterations in pelvic neuronal and vascular networks, The complex pathophysiological relationship between testosterone (T) deficiency (TD) and the constellations LUTS, and metabolic dysfunction manifested in the metabolic syndrome (Met S) remains poorly understood. TD has emerged as one the potential targets by which Met S may contribute to the onset and development as well as worsening of LUTS. Because it has been recognized that treatment of men with Met S with T therapy ameliorates Met S components, it is postulated that T therapy may represent a therapeutic target in improving LUTS. Furthermore, the effect of TD on the prostate remains unclear, and often debatable. It is believed that T exclusively promotes prostate growth, however recent evidence has strongly contradicted this belief. The true relationship between benign prostatic hyperplasia, TD, and LUTS remains elusive and further research will be required to clarify the role of T in both benign prostatic hypertrophy (BPH) and LUTS as a whole. Although there is conflicting evidence about the benefits of T therapy in men with BPH and LUTS, the current body of literature supports the safety of using this therapy in men with enlarged prostate. As the population afflicted with obesity epidemic continues to age, the number of men suffering from Met S and LUTS together is expected to increase.

show abstract

“…Within the published literature, male hypogonadism and its related comorbidities appear associated with poor clinical outcomes, [19][20][21][22][23] increased economic burden on healthcare systems, [24][25][26] and burdensome patient-reported symptoms. [27][28][29] Specific to comorbidities, limited data were available on the burden of obesity and T2DM in patients with male hypogonadism, which may be associated with the close link between these diseases.…”

Section: Burden Of Male Hypogonadism and Related Comorbiditiesmentioning

confidence: 99%

“…In addition to its overall clinical and economic burden, male hypogonadism is also associated with negative impacts on individual patients' experiences, through burdensome patient-reported symptoms, 27,28 and reduced quality of life. 29 In a prospective study of men in Taiwan (n=680), risk of erectile dysfunction (defined as scoring ≤7 on the International Index of Erectile Function) was significantly increased in men with low testosterone: ×2.4 with total testosterone <11 nmol/L, and ×3.0 with free testosterone <0.23 nmol/L (p<0.05).…”

Section: Burdensome Patient-reported Symptomsmentioning

confidence: 99%

Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review

Yeo¹,

Holl²,

Peñaherrera³

et al. 2021

CEOR

View full text Add to dashboard Cite

Male hypogonadism and major comorbidities such as type 2 diabetes mellitus, obesity, cardiovascular disease, and osteoporosis appear closely connected, forming a vicious cycle that leads to further hypogonadism. This narrative review provides a comprehensive overview of the current literature on the overall burden of male hypogonadism alongside related comorbidities, and how this may be alleviated through testosterone therapy. Observational and clinical data demonstrate that the interaction of male hypogonadism and its related comorbidities is associated with increased mortality, cardiovascular event risk and reduced quality of life. Evidence from epidemiological and registry-based studies shows that this clinical and humanistic burden translates to increased economic burden on health-care systems, through increased physician visits, medical claims, and drug costs. Male hypogonadism can be managed with testosterone therapy, which is intended to normalize testosterone concentrations and thereby reduce both hypogonadism symptoms and risk of comorbidities. Clinical and observational data suggest that in males with hypogonadism, testosterone therapy rapidly and sustainably improves glycemia, reduces risk of progression to diabetes, leads to significantly reduced waist circumference and fat mass, while providing significant positive effects on cardiovascular event risk and bone density. Significant and sustained improvement in patient-reported erectile function, urinary function, and aging male symptoms have also been shown. Economic evaluations have estimated that reduced comorbidity risk following testosterone therapy may lead to cost-savings, with one study estimating yearly inpatient savings of £3732 for treating comorbidities after intervention. A major unmet need exists in the area of male hypogonadism, particularly related to common comorbidities. Options for treatment include testosterone therapy, which has been shown to alleviate the clinical, economic, and humanistic burden associated with these conditions. As the prevalence of male hypogonadism is likely to increase globally, and this condition may be currently underdiagnosed, cost-saving testosterone therapies should be increasingly considered to manage hypogonadism.

show abstract

Serum Testosterone Levels Are Negatively Correlated with International Prostate Symptom Score and Transitional Prostate Volume

Abstract: As total testosterone levels decrease, both International Prostate Symptom Score and transitional prostate volume increase significantly. These findings provide evidence of the presence of more severe lower urinary tract symptoms and larger transitional prostate volume in aging men.

Cited by 13 publications

References 26 publications

How do testosterone and prostate‐specific antigen levels affect the prostate volume in patients with spinal cord injury?

How do testosterone and prostate‐specific antigen levels affect the prostate volume in patients with spinal cord injury?

Impact of Testosterone Deficiency and Testosterone Therapy on Lower Urinary Tract Symptoms in Men with Metabolic Syndrome

Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review

Contact Info

Product

Resources

About